Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Queensland Health
Julphar
McKesson
Merck
Fish and Richardson
Fuji
Federal Trade Commission
Express Scripts
Novartis

Generated: October 19, 2017

DrugPatentWatch Database Preview

INVEGA TRINZA Drug Profile

« Back to Dashboard

What is the patent landscape for Invega Trinza, and what generic Invega Trinza alternatives are available?

Invega Trinza is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has forty-eight patent family members in thirty-six countries and thirteen supplementary protection certificates in ten countries.

The generic ingredient in INVEGA TRINZA is paliperidone palmitate. There are thirty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

Summary for Tradename: INVEGA TRINZA

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list75
Clinical Trials: see list11
Patent Applications: see list11
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:INVEGA TRINZA at DailyMed

Pharmacology for Tradename: INVEGA TRINZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-001May 18, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-004May 18, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-002May 18, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-004May 18, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-001May 18, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-002May 18, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-003May 18, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA TRINZA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-003May 18, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: INVEGA TRINZA

Country Document Number Estimated Expiration
Indonesia16927► Subscribe
China1093762► Subscribe
Argentina007194► Subscribe
European Patent Office0904081► Subscribe
Canada2236691► Subscribe
South Africa9704331► Subscribe
Norway981984► Subscribe
Austria208619► Subscribe
Bulgaria62684► Subscribe
World Intellectual Property Organization (WIPO)9744039► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INVEGA TRINZA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00491Netherlands► SubscribePRODUCT NAME: PALIPERIDONPALMITAAT; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
C/GB11/044United Kingdom► SubscribePRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
2011008Lithuania► SubscribePRODUCT NAME: PALIPERIDONI PALMITAS; REGISTRATION NO/DATE: EU/1/11/672/001 - EU/1/11/672/006 20110304
90023-0Sweden► SubscribePRODUCT NAME: PALIPERIDONPALMITAT; REG. NO/DATE: EU/1/11/672/001-006 20110304
842Luxembourg► Subscribe91842, EXPIRES: 20220512
C/GB07/065United Kingdom► SubscribePRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
11/021Ireland► SubscribePRODUCT NAME: PALIPERIDONE PALMITATE ESTER; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
2011 00020Denmark► Subscribe
2011008,C0904081Lithuania► SubscribePRODUCT NAME: PALIPERIDONI PALMITAS; REGISTRATION NO/DATE: EU/1/11/672/001 - EU/1/11/672/006 20110304
0904081/01Switzerland► SubscribePRODUCT NAME: PALIPERIDON PALMITATESTER; REGISTRATION NO/DATE: SWISSMEDIC 60466 20101215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
Mallinckrodt
Queensland Health
Novartis
Moodys
Chubb
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot